Clinical Trials Logo

Filter by:
NCT ID: NCT01228045 Active, not recruiting - Gastric Cancer Clinical Trials

A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The investigators hypothesis is that the combination of TS-ONE with cisplatin and trastuzumab is safe and as effective as combination treatment for HER2 positive gastric cancer.

NCT ID: NCT01227772 Active, not recruiting - Gastric Cancer Clinical Trials

Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve survival of patients with advanced Gastric Cancer.

NCT ID: NCT01227733 Active, not recruiting - Breast Cancer Clinical Trials

Comparative Genomic and Genetic Analysis of Paired Primary Breast - Metastatic Tumor Specimens Using High-throughput Platforms

Start date: August 2010
Phase: N/A
Study type: Observational

Adequate quality and quantity of RNA may be extracted from paraffin-embedded tumor blocks for gene expression analysis. This has clinical relevance as gene expression signatures may then be profiled using archival tumor blocks, which are more readily available than frozen tissues.

NCT ID: NCT01226316 Active, not recruiting - Ovarian Cancer Clinical Trials

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Start date: December 1, 2010
Phase: Phase 1
Study type: Interventional

This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future. This study will also investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug). This study will also investigate anti-tumour activity of AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid cancers bearing either AKT1 / PIK3CA or PTEN mutation.

NCT ID: NCT01189903 Active, not recruiting - Clinical trials for Asian Colorectal Cancer Patients

Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

Start date: January 2011
Phase: Phase 2/Phase 3
Study type: Interventional

1. Primary Endpoints - Biomarker data suggestive of regorafenib-mediated inhibition of the RAS-RAF- MEK-ERK signal transduction pathway,of various tyrosine kinase receptors and/or of angiogenesis. - Evaluation of potential relationships between biomarker data and clinical activity. - Evaluation of a novel biomarker technology (Prometheus COPIA platform) 2. Secondary Endpoints - Biomarker data suggestive of regorafenib-mediated effects on circulating rare cells. - Comparison of tumor genetic profiles obtained using DNA isolated from plasma, tumor biopsies and circulating tumor cells. - Patient safety data - Pharmacokinetics of regorafenib - Changes in tumor metabolic activity as measured by PET CT scan (optional)

NCT ID: NCT01174875 Active, not recruiting - Metabolic Diseases Clinical Trials

Growing Up in Singapore Towards Healthy Outcomes

GUSTO
Start date: June 2009
Phase:
Study type: Observational

This study aims to test the following hypotheses in women recruited in early pregnancy and whose children will be followed up till at least 14 years of age. - Epigenetic changes in conceptual tissues obtained at birth reflect the environment that the fetus was exposed to during development. - The pattern of epigenetic marks in gene promoters obtained from DNA in birth tissues, together with genotype, phenotype, and environmental exposures, can be utilized to assess how the perinatal environment affects subsequent metabolic, neurodevelopmental and other phenotypes.

NCT ID: NCT01135056 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

SIRveNIB
Start date: July 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS). The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.

NCT ID: NCT01100814 Active, not recruiting - Gastric Cancer Clinical Trials

Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer

Start date: September 2011
Phase: N/A
Study type: Observational

The investigators hypothesize that aberrant hypermethylation of tumour suppressor genes is an important mechanism for Epstein-Barr Virus (EBV) - related gastric carcinogenesis, the promoter hypermethylation status and the expression of S100A2 and TFF1 might be different between EBV-associated gastric cancer (GC) and non EBV-associated GC.

NCT ID: NCT01078779 Active, not recruiting - Influenza Clinical Trials

The Chloroquine for Influenza Prevention Trial

CHIP
Start date: November 2009
Phase: Phase 2
Study type: Interventional

A randomised controlled trial to determine the efficacy of chloroquine for the prevention of influenza

NCT ID: NCT01065454 Active, not recruiting - Clinical trials for Hypertension, Pulmonary

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

LEPHT
Start date: April 14, 2010
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction